Quick Answer
Xeris Biopharma Holdings, Inc. reported Net Income of $554.0 thousand for fiscal year 2025.
Xeris Biopharma Holdings, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | $554.0K | +101.0% |
| 2024 | -$54.84M | +11.9% |
| 2023 | -$62.26M | +34.2% |
| 2022 | -$94.66M | +22.9% |
| 2021 | -$122.72M | -34.7% |
| 2020 | -$91.14M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $621.0K | +103.9% | +132.2% |
| June 30, 2025 | -$1.93M | +87.2% | +79.1% |
| March 31, 2025 | -$9.22M | +51.4% | +41.4% |
| September 30, 2024 | -$15.74M | -29.1% | -4.9% |
| June 30, 2024 | -$15.01M | +24.4% | +20.9% |
| March 31, 2024 | -$18.98M | -12.7% | -55.7% |
| September 30, 2023 | -$12.19M | +44.2% | +38.6% |
| June 30, 2023 | -$19.84M | +24.2% | -17.9% |
- Xeris Biopharma Holdings, Inc. showed an increase of +101.0% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, Xeris Biopharma Holdings, Inc.’s net income has grown by 100.6% (from -$91.14 million to $554.0 thousand).
- The most recent figure is from Xeris Biopharma Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: